Scarica l'app Stockscreener
2.14
1.90%
0.04
Dopo l'orario di chiusura:
2.14
Precedente Chiudi:
$2.10
Aprire:
$2.14
Volume 24 ore:
734.71K
Relative Volume:
0.77
Capitalizzazione di mercato:
$172.42M
Reddito:
$52.74M
Utile/perdita netta:
$-6.60M
Rapporto P/E:
-25.33
EPS:
-0.0845
Flusso di cassa netto:
$-13.63M
1 W Prestazione:
+12.63%
1M Prestazione:
-1.83%
6M Prestazione:
+16.94%
1 anno Prestazione:
+32.10%
Intervallo 1D:
$2.10
$2.16
Intervallo di 1 settimana:
$1.90
$2.16
Portata 52W:
$1.32
$3.19
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Nome
Protalix BioTherapeutics Inc.
Settore
Industria
Telefono
972 4 988 9488
Indirizzo
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.14 | 169.20M | 52.74M | -6.60M | -13.63M | -0.0845 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-17 | Reiterato | Rodman & Renshaw | Buy |
| 2016-04-04 | Iniziato | Rodman & Renshaw | Buy |
| 2015-04-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2014-11-12 | Reiterato | R. F. Lafferty | Buy |
| 2014-01-24 | Iniziato | R. F. Lafferty | Buy |
| 2012-05-02 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Reiterato | Oppenheimer | Outperform |
| 2012-04-30 | Downgrade | Auriga | Buy → Hold |
| 2011-10-13 | Iniziato | Morgan Joseph | Hold |
| 2011-03-17 | Downgrade | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Reiterato | Oppenheimer | Outperform |
| 2010-10-14 | Reiterato | UBS | Buy |
| 2009-12-02 | Reiterato | Hapoalim | Outperform |
| 2009-09-22 | Iniziato | Canaccord Adams | Buy |
| 2009-09-02 | Iniziato | Hapoalim | Outperform |
| 2008-12-01 | Reiterato | Oppenheimer | Outperform |
| 2008-03-11 | Iniziato | UBS | Buy |
| 2007-11-20 | Iniziato | CIBC Wrld Mkts | Sector Outperform |
Mostra tutto
Protalix BioTherapeutics Inc. Borsa (PLX) Ultime notizie
PLX Stock Price, Quote & Chart | PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) - ChartMill
Protalix Highlights Elfabrio Dosing Approvals and Growth Plans - TipRanks
Protalix BioTherapeutics Advances Rare Disease Treatments with Elfabrio® and PRX-115, Achieves Key Regulatory and Pipeline Milestones - Minichart
Protalix BioTherapeutics (PLX) posts new May 2026 corporate presentation for investors - Stock Titan
Protalix BioTherapeutics appoints Gilad Mamlok as CFO - MSN
Protalix BioTherapeutics (PLX) Q1 2026 8-K: EPS Not Disclosed, R - GuruFocus
Protalix reaffirms $78M-$83M 2026 revenue outlook following $25M Elfabrio milestone - MSN
Protalix Q1 Call: Milestone-Fueled Profit, Bold Targets - The Globe and Mail
PLX: Chiesi milestone received - MSN
PLX: Chiesi Milestone Received - Yahoo Finance
Protalix BioTherapeutics 1Q Rev $33.8M >PLX - Moomoo
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call Transcript - Insider Monkey
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results - Sahm
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlig - GuruFocus
Protalix BioTherapeutics Delivers 234% Revenue Growth in Q1 2026 - AlphaStreet
Protalix BioTherapeutics Releases Q1 2026 Financial Results - AlphaStreet
Protalix BioTherapeutics, Inc. Q1 2026 Financial Results & SEC 10-Q Filing Overview - Minichart
Protalix BioTherapeutics Reports Q1 2026 Results: $18.3M Net Income, $25M Milestone From Chiesi, and Strong Guidance for 2026 - Minichart
Protalix BioTherapeutics Backs 2026 Rev $78M-$83M >PLX - Moomoo
Protalix BioTherapeutics (PLX) Reports Q1 Earnings with Strong R - GuruFocus
Earnings call transcript: Protalix Q1 2026: Earnings beat expectations, stock rises By Investing.com - Investing.com South Africa
PLX: $25M milestone drives strong Q1, with 2026 guidance reaffirmed and pipeline advancing - TradingView
Earnings call transcript: Protalix Q1 2026: Earnings beat expectations, stock rises - Investing.com
Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call - Yahoo Finance
Protalix BioTherapeutics 1Q 2026: Revenue $33.75M, Net income $18.32M, EPS $0.22— 10-Q Summary - TradingView
Protalix Hits Profitability, Fuels Pipeline with Elfabrio Milestone - BriefGlance
Protalix (PLX) turns Q1 2026 profit as Elfabrio EU milestone boosts cash - Stock Titan
Protalix reports Q1 2026 net income $18.3M on $33.8M revenue, $25M Chiesi milestone - TradingView
Protalix: Q1 Earnings Snapshot - marketscreener.com
BRIEF-Protalix BioTherapeutics Q1 EPS USD 0.23 - TradingView
Protalix BioTherapeutics 1Q EPS 22c >PLX - Moomoo
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 - Barchart.com
Protalix BioTherapeutics Q1 earnings preview - MSN
Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors? - MSN
Earnings Preview: PLX to Report Financial Results Pre-market on May 13 - Moomoo
Protalix to discuss quarterly results and business update May 13 - Stock Titan
MSN Money - MSN
Protalix BioTherapeutics (PLX) sets 2026 director, pay and stock plan votes - Stock Titan
[ARS] Protalix BioTherapeutics, Inc. SEC Filing - Stock Titan
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy - MSN
Protalix CFO updates Form 3 share and option holdings | PLX Insider Trading - Stock Titan
PLX News | PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) - ChartMill
Protalix BioTherapeutics (NYSE:PLX) Stock Price Down 2.2%Here's Why - MarketBeat
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 - Quantisnow
Protalix: Elfabrio Struggles Against Oral Competition (NYSE:PLX) - Seeking Alpha
Aug Chart Watch: Is Protalix BioTherapeutics Inc currently under institutional pressure2026 Growth vs Value & Fast Moving Stock Watchlists - baoquankhu1.vn
Is Protalix (PLX) Stock entering maturity stage | Price at $2.26, Up 3.20%Earnings Breakout - Newser
Targets Report: What is Protalix BioTherapeutics Incs valuation compared to sectorIPO Watch & Risk Controlled Daily Trade Plans - baoquankhu1.vn
PLX Technical Analysis & ETF Price Forecast - Intellectia AI
Protalix BioTherapeutics Inc. Azioni (PLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):